echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > ESMO Blockbuster | General Assembly: First-line immune monotherapy significantly improves OS in patients with poor prognosis in NSCLC

    ESMO Blockbuster | General Assembly: First-line immune monotherapy significantly improves OS in patients with poor prognosis in NSCLC

    • Last Update: 2022-09-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    The Annual Meeting of the European Society of Oncology (ESMO) is the most prestigious and influential oncology conference



    background

    Several studies have shown that first-line immunotherapy ± chemotherapy significantly improve overall survival (OS) compared with chemotherapy


    method

    Patients without driver gene mutations, poor PS (≥2), or patients with complications >70 years of age who are not eligible for locally advanced/metastatic NSCLC receiving platinum-containing dual-agent chemotherapy are included in the study


    outcome

    A total of 453 patients were enrolled in the study and were randomly assigned to the altenizumab group (302 cases) and the chemotherapy group (151 cases


    conclusion

    Regardless of histological type, PD-L1 expression, and ECOG PS score, first-line atenizizumab significantly improved OS (HR=0.


    78) unsuitable for platinum patients compared with chemotherapy, and the estimated number of patients who survived at 2 years of atenizumab treatment was twice as high as
    chemotherapy.

    Compared with chemotherapy, atenizumab was steadily associated with health-related quality of life and improved TTCDs
    in patients.

    Regardless of the subgroup, the IPSOS study was the first prospective study to show an improved prognosis of os in patients with poor prognosis in NSCLC, with no new adverse events and a guarantee of quality of life
    。 References: LBA11-IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a Platinumcontaining regimen.
    2022 ESMO.
    Edit: Xiaoyuan Layout: Xiaoyuan Execution: Uni
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.